Posts by Markus Gershater, PhD
Why Quality by Design (QbD) is vital for pharmaceutical R&D
Understand Quality by Design (QbD), the key jargon surrounding it, plus learn why it’s so important to bake into your development processes from the start.

Filter by Topic
About the Author
Markus is a co-founder of Synthace and one of the UK’s leading visionaries for how we, as a society, can do better biology. Originally establishing Synthace as a synthetic biology company, he was struck with the conviction that so much potential progress is held back by tedious, one-dimensional, error-prone, manual work. Instead, what if we could lift the whole experimental cycle into the cloud and make software and machines carry more of the load? He’s been answering this question ever since.
Markus holds a PhD in Plant Biochemistry from Durham University. He was previously a research associate in synthetic biology at University College London and a Biotransformation Scientist at Novacta Biosystems.
How AI is (so close to) transforming drug discovery
AI won't change biology unless we change with it
We need biology in the fight against climate change.
Old lab software can't solve today's R&D problems
Why biology needs a digital model for experiments
High Dimensional Experimentation: a new era for assay development
Are ELNs a Dead End?
Too many hats: How biology drains biologists
COVID vaccine development was astonishing, but it's not over
